、多肽产业催化不断，持续布局医药底部机会医药生物-医药生物行业周报证券研究报告/行业周报2023年11月12日评级：增持（维持）[重Ta点bl公e_司Fi基na本nc状e]况分析师：祝嘉琦公司名称股价EPSPEPEG评级执业证书编号：S0740519040001电话：021-2031515020222023E2024E2025E20222023E2024E2025E1.48买入Email：zhujq@zts.com.cn3.33买入分析师：崔少煜迈瑞医疗285.217.929.E5311.4713.7935.9929.9224.8620.680.96买入执业证书编号：S07405220600010.730.881.0579.0266.1855.2246.041.40买入Email：cuisy@zts.com.cn恒瑞医药48.390.613.314.215.4029.7126.6820.9616.320.63买入1.311.652.1047.0237.3229.5323.281.16买入药明康德88.192.973.784.716.0620.1116.7213.4110.431.27买入0.961.241.6645.1836.0227.9920.951...